Meropenem + Vaborbactam - Carbapenem and Novel Boronic Acid ß-Lactamase Inhibitor

Meropenem + Vaborbactam is a fixed dose combination of a carbapenem and a novel boronic acid β-lactamase inhibitor of class A and class C serine β-lactamases, that was specifically developed to inhibit Carbapenem-Resistant Enterobacterales (CRE), including Klebsiella Pneumoniae Carbapenemase (KPC)-producing bacteria. Meropenem exerts bactericidal activity by inhibiting peptidoglycan cell wall synthesis as a result of binding to and inhibition of activity of essential penicillin-binding proteins (PBPs). Vaborbactam forms covalent adduct with β-lactamases and is stable to β-lactamase-mediated hydrolysis. Meropenem / Vaborbactam has been approved in the US and in EU for the treatment of complicated urinary tract infections (cUTI) including acute pyelonephritis. In Europe it has been also approved for the treatment of complicated intra-abdominal infections (cIAI) and hospital-acquired bacterial pneumonia (HABP), such as ventilator associated bacterial pneumonia (VABP).